- Entry
- $1.78
- Final
- $2.59 +45.5%
- Target
- —
- Score
- +1.00
Black Diamond Therapeutics (BDTX) is a clinical stage company developing treatments against lung and brain cancer. Whilst it’s performance since IPO has been extremely poor, the narrative is now completely different. Few years ago the company was taken over by a new CEO with several successful exits in the pharma space. The result - 1 drug (BDTX-1535) scheduled to complete it’s Phase 2 trials at the end of the year and get regulatory feedback in Q4 on a path to …
— ORIGINAL POST ·
BDTX - Why I’m all in on this stock
· r/investing
· May 5, 2025